Investment Thesis — Corcept Therapeutics Incorporated
The market is severely mispricing Corcept Therapeutics, over-discounting the patent cliff risk for Korlym while failing to adequately value the significant potential of its pipeline, particularly relacorilant. The current valuation implies a near-total loss of future earnings, which is overly pessimistic given the unmet medical need and potential for new drug approvals.
Catalysts
- Positive clinical trial results or regulatory approval for relacorilant in Cushing's syndrome.
- Favorable resolution of ongoing patent litigation for Korlym, extending exclusivity or enabling a smoother transition.
- Announcement of new pipeline assets or expansion of relacorilant into additional indications.
Risk Factors
- Failure of relacorilant to gain regulatory approval or achieve significant commercial success post-launch.
- Unfavorable outcome in patent litigation, leading to earlier-than-expected generic competition for Korlym.
- Increased competition in the Cushing's syndrome market from new or existing therapies.
Key Debates
CORT's 92x Fwd P/E justified by 25%+ FY25 growth by Q4.
Short squeeze pushes CORT above $50 by H2.
CORT reaches $68.40 analyst PT by Q3 as growth accelerates.